Resource Center
Find the latest content and resources from our team of experts to keep you in the know for all things quality and regulatory in the life science industry.
Sort by topic
Sort by resource type
Recognition underscores the firm’s continued commitment to championing women in leadership and excellence in ...
EU pharmaceutical reform is one of the most significant regulatory developments impacting the life ...
Artificial intelligence is becoming embedded across clinical development, manufacturing, and quality operations. ...
Nitrosamine impurities continue to be a major focus for regulators—and in 2026, scrutiny is not slowing down.
The U.S. Food and Drug Administration is expanding its use of remote and hybrid inspection models, incorporating ...
mRNA technology, which gained global prominence during the COVID-19 pandemic, has since expanded into broader ...
mRNA technology, which gained global prominence during the COVID-19 pandemic, has since expanded into broader ...
A recent $2.7 billion agreement between Eli Lilly and an artificial intelligence-driven drug discovery company is ...
This whitepaper outlines a structured approach to responding to FDA Warning Letters, with a focus on root cause ...
The U.S. Food and Drug Administration is placing increased scrutiny on change control systems across ...
Technology transfer has always been a critical step in bringing products from development to commercial ...
A Warning Letter is issued when the FDA identifies significant violations that have not been adequately addressed ...
No results found.